OliX Pharmaceuticals, Inc. engages in the research and development of treatments and the manufacture and sale of new drugs. It develops technology acid-based therapeutics based on ribonucleic acid interference (RNAi) technology. It offers hypertrophic scar treatments, subretinal fibrosis treatments, rod-cone dystrophy treatments, age-related macular degeneration products, and others. The company was founded by Dong-ki Lee on February 26, 2010 and is headquartered in Suwon-si, South Korea.